Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · IEX Real-Time Price · USD
47.50
-0.02 (-0.04%)
At close: Jul 19, 2024, 4:00 PM
47.52
+0.02 (0.04%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Apogee Therapeutics Employees
Apogee Therapeutics had 9 employees as of March 1, 2024. The number of employees decreased by 16 or -64.00% since the number was reported on June 22, 2023.
Employees
9
Change
-16
Growth
-64.00%
Revenue / Employee
n/a
Profits / Employee
-$11,506,000
Market Cap
2.78B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 1, 2024 | 9 | -16 | -64.00% |
| Jun 22, 2023 | 25 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,270 |
| Tandem Diabetes Care | 2,400 |
| Certara | 1,391 |
| Progyny | 566 |
| MorphoSys AG | 524 |
| Agios Pharmaceuticals | 386 |
| SpringWorks Therapeutics | 227 |
| Kymera Therapeutics | 187 |
APGE News
- 7 weeks ago - Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD - GlobeNewsWire
- 2 months ago - Apogee Therapeutics to Participate in Upcoming June Investor Conferences - GlobeNewsWire
- 2 months ago - Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases - GlobeNewsWire
- 2 months ago - Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference - GlobeNewsWire
- 4 months ago - Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases - GlobeNewsWire
- 4 months ago - Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million - GlobeNewsWire
- 4 months ago - Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering - GlobeNewsWire